U.S. markets closed
  • S&P 500

    3,870.29
    -31.53 (-0.81%)
     
  • Dow 30

    31,391.52
    -143.99 (-0.46%)
     
  • Nasdaq

    13,358.79
    -230.04 (-1.69%)
     
  • Russell 2000

    2,231.51
    -43.81 (-1.93%)
     
  • Crude Oil

    59.65
    -0.99 (-1.63%)
     
  • Gold

    1,733.10
    +10.10 (+0.59%)
     
  • Silver

    26.83
    +0.15 (+0.57%)
     
  • EUR/USD

    1.2092
    +0.0032 (+0.27%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • GBP/USD

    1.3958
    +0.0038 (+0.27%)
     
  • USD/JPY

    106.7510
    +0.0210 (+0.02%)
     
  • BTC-USD

    47,837.91
    -935.63 (-1.92%)
     
  • CMC Crypto 200

    955.41
    -31.25 (-3.17%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Myriad Genetics, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the company’s transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021.

Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the company’s genetic insights. The presentation will be available via a live audio webcast accessible at the following direct link or through the investor information section of Myriad’s website at www.myriad.com.

About Myriad Genetics

Myriad Genetics Inc., is a leading precision medicine company dedicated improving and transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across in specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more information, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Media Contact:

Investor Contact:

Jared Maxwell

Scott Gleason

(801) 505-5027

(801) 584-1143

jmaxwell@myriad.com

sgleason@myriad.com